COMPANY

Evergreen Therapeutics

HQ: Bethesda, MD (US office) source · egmedai.com ↗

Keywords: cognitive impairment dry age-related macular degeneration pre-eclampsia Advanced Endometrial Cancer Neuropsychiatric Systemic Lupus Erythematosus Systemic Lupus Erythematosus Non-Exudative (Dry) Age-related Macular Degeneration (dAMD) COVID-19 Pneumonia EG-007 EG-101 EG-501 EG-301 EG-009A

Location: Bethesda, MD (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

2026-12 Trial start Phase 3: Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer source ↗
2026-08 Trial start Phase 2: Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem source ↗
2026-06 Trial start Phase 1: Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia source ↗
2026-06 Trial start Phase 2: Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD source ↗
Mar 4, 2022 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia source ↗
Aug 23, 2018 Trial start Phase 2: EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 1 · Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia · NCT07327255
2027-03 (ESTIMATED) · Phase 2 · Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem · NCT05106127
2027-12 (ESTIMATED) · Phase 3 · Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer · NCT05077215
2028-06 (ESTIMATED) · Phase 2 · Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD · NCT05170048

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07327255	Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia	Phase 1	Not yet recruiting	2026-06	2027-03 (estimated)
NCT07281105	EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study	Phase 2	Completed	Aug 23, 2018	Aug 12, 2025 (actual)
NCT05170048	Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD	Phase 2	Not yet recruiting	2026-06	2028-06 (estimated)
NCT05077215	Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Phase 3	Not yet recruiting	2026-12	2027-12 (estimated)
NCT05106127	Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem	Phase 2	Not yet recruiting	2026-08	2027-03 (estimated)
NCT04561180	Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia	Phase 2	Withdrawn	Mar 4, 2022	May 1, 2023 (actual)